43
Smilies
Enter your email and we will let you know as soon as the product arrives
According to the National Institutes of Health, approximately 17 million Americans suffer from urinary incontinence (UI) and 30 million from overactive bladder (OAB). In addition to the urgent need to urinate, frequent urination, and nocturia, one in three patients suffering from an overactive bladder also suffers from incontinence. The problem is constantly spreading and affects people of all ages, including children and young adults. Recent research has shown that Hormone Replacement Therapy (HRT) contributes to the appearance and worsening of incontinence, as collagen that supports the bladder and surrounding area weakens.
The mechanism of action of Vesteva™ is believed to improve the collagen and connective tissue of the bladder and surrounding area, without causing side effects such as dry mouth, dry eyes, vision blurriness, and memory loss. Thus, the action of Vesteva™ gradually increases within one to two months, with 50% of trial participants noting improvement at one month and 80 - 85% optimal results after two months of use.
A randomized, double-blind, placebo-controlled trial presented at the Experimental Biology Conference in April 2006 in San Francisco evaluated the effectiveness of the Vesteva™ formula in reducing symptoms of overactive bladder and urinary incontinence in 98 participants. The results showed that by the second month, participants demonstrated a greater response in reducing frequent urination and incontinence compared to the placebo. Patients who received the Vesteva™ formula showed improvement in the frequency of daily urination, the frequency of nighttime urination (nocturia), the frequency of daytime incontinence episodes, and the frequency of nighttime incontinence episodes.
